Inzomelid, a selective, orall small molecule inhibitor of the NLRP3 inflammasome, has been tested in a phase I trial of CAPS (Cryopyrin-Associated Periodic Syndrome) https://t.co/8gO63xO9bC
Inzomelid, a selective, orall small molecule inhibitor of the NLRP3 inflammasome, has been tested in a phase I trial of CAPS (Cryopyrin-Associated Periodic Syndrome) https://t.co/8gO63xO9bC
TO THE NEW MONTHLY EMAIL